Factors associated with albumin loss in post-dilution hemodiafiltration and nutritional consequences.
BACKGROUND
Hemodiafiltration is currently one of the most effective techniques of extra-renal purification but results in an increase of albumin loss in dialysate. We aimed to determine the factors associated with albumin loss during post-dilution hemodiafiltration, compare an "automatic" mode of infusate flow control versus a "manual" control, and assess the potential nutritional impact.


METHODS
This prospective observational study included all hemodialysis patients in our institution who underwent post-dilution hemodiafiltration 3 times a week on a Fresenius 5008 for at least 2 months. At each session, albumin content was measured in a representative effluent dialysate volume. The automatic mode of the Fresenius 5008 was used for automatic infusate flow control.


RESULTS
In all, 18 patients (mean age 60.7 ± 15 years) underwent 85 post-dilution hemodiafiltration sessions. The mean albumin loss was 3134 ± 2450 mg/session. Albumin loss was significantly affected by infusate flow, infusate volume, transmembrane pressure and ultrafiltration volume. The loss was greater with Toraysulfone and FX 1000 membranes rather than FX 80 or FX 100 membranes. With AutoSub rather than manual control, infusate flow was greater (P<.001), transmembrane pressure was higher (P = .004), and the albumin loss was greater (P = .010). However, there was no correlation between albumin loss and nutritional variables.


CONCLUSIONS
Albumin loss during post-dilution hemodiafiltration was correlated with increased transmembrane pressure and infusate flow, especially AutoSub flow control, and type of membrane. However, this loss, when moderate, did not seem to affect nutritional aspects and should not limit the use of hemodiafiltration.
Nephrology-Hemodialysis Department, CHRU Tours, Tours - France.
Anne
A
Fournier
Béatrice
B
Birmelé
Maud
M
François
Louis
L
Prat
Jean-Michel
JM
Halimi
D000368:Aged; D015415:Biomarkers / Q000097:blood; D004867:Equipment Design; D005260:Female; D005602:France; D017583:Hemodiafiltration / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D015596:Nutrition Assessment; D009752:Nutritional Status; D011446:Prospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000378:metabolism*; D000075462:Serum Albumin, Human; D016896:Treatment Outcome
C422455:ALB protein, human; D015415:Biomarkers; D008567:Membranes, Artificial; D012709:Serum Albumin; D000075462:Serum Albumin, Human